August 2025

Health insurers commit to reforming prior authorization processes, aiming to enhance patient care and reduce burdens on providers, impacting millions.

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.

The author discusses how Principal Care Management (PCM) enhances oncology care, improves patient outcomes, and boosts reimbursement opportunities for providers, yet remains underutilized.

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.

International Myeloma Foundation Chief Medical Office Joseph Mikhael, MD, shares how the M-Power initiative is addressing disparities through community engagement, education, and improved clinical trial access.

Linvoseltamab gains FDA approval as an effective off-the-shelf therapy for relapsed multiple myeloma, showcasing impressive response rates and safety profiles.

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.